Gilead Sciences (GILD)

• Market cap: $114B
• 1 day: 0.21%
• 5 days: 1.71%
• 1 month: -1.03%
• 3 months: 5.13%
• 6 months: 25.29%
• Year to date: -0.04%
• 1 year: 6.20%
• 5 years: 45.82%
• 10 years: -11.51%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 18,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

47% more first-time investments, than exits

New positions opened: 169 | Existing positions closed: 115

38% more funds holding in top 10

Funds holding in top 10: 13 [Q2] → 18 (+5) [Q3]

18% more capital invested

Capital invested by funds: $73.5B [Q2] → $86.4B (+$12.9B) [Q3]

2% more funds holding

Funds holding: 1,647 [Q2] → 1,681 (+34) [Q3]

3% more call options, than puts

Call options by funds: $965M | Put options by funds: $941M

2.42% less ownership

Funds ownership: 85.31% [Q2] → 82.89% (-2.42%) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 613 | Existing positions reduced: 683

Research analyst outlook

19 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $80 13% downside
• Avg. target: $101 10% upside
• High target: $125 36% upside

19 analyst ratings

• positive: 12 63%
• neutral: 7 37%
• negative: 0 0%

Morgan Stanley Matthew Harrison 35% 1-year accuracy 6 / 17 met price target	23% upside $113	Overweight Upgraded	10 Jan 2025
Cantor Fitzgerald Olivia Brayer 27% 1-year accuracy 6 / 22 met price target	13% downside $80	Neutral Reiterated	11 Dec 2024
RBC Capital Brian Abrahams 13% 1-year accuracy 10 / 79 met price target	9% downside $84	Sector Perform Reiterated	11 Dec 2024
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target	19% upside $109	Buy Reinstated	10 Dec 2024
Oppenheimer Matthew Biegler 11% 1-year accuracy 3 / 28 met price target	25% upside $115	Outperform Reiterated	10 Dec 2024